Info

🌱 來自: Metastatic Colon Cancer

BRAF V600E

• Regorafenib

non-small cell lung cancer

• 4%, RET Fusion 1%, NTRK1/2/3 Fusion <1%, HER2 Amp/Mt 3%, High-level MET Amp <1% (JAMA 2014;311:1998)
• Rx Dabrafenib + trametinib (ORR 64%, PFS 10.9 mos) (Lancet Onc 2017;18:1307)